Skip to main content
Home

Search


NEI on Social Media | Search A-Z | en español | Text size S M L
  • About NEI
    • NEI Research Accomplishments
    • Budget and Congress
    • About the NEI Director
    • History of the NEI
    • NEI 50th Anniversary
    • NEI Women Scientists Advisory Committee (WSAC)
    • Board of Scientific Counselors
    • National Advisory Eye Council (NAEC)
    • Donating to the NEI

    Menu About NEI Block

     Contact Us

     Visiting the NIH Campus

    Mission Statement

    As part of the federal government’s National Institutes of Health (NIH), the National Eye Institute’s mission is to “conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.”

  • News & Events
    • Events Calendar
    • NEI Press Releases
    • News from NEI Grantees
    • Spokesperson bios
    • Statistics and Data
    • Resources for the media

    Pressroom Contacts

    Dustin Hays - Chief, Science Communication
    dustin.hays@nih.gov

    Kathryn DeMott, Media Relations
    Kathryn.DeMott@nih.gov

    NEI Office of Communications
    (301)496-5248

  • Health Information
    • Frequently asked questions
    • Clinical Studies
    • Spanish Language Information
    • Publications Catalog
    • Photos and Images
  • Grants and Funding
    • Extramural Research
    • Division of Extramural Science Programs
    • Division of Extramural Activities

    Extramural Contacts

    National Eye Institute
    Division of Extramural Research
    6700B Rockledge Dr., MSC 6914
    Bethesda, MD 20892
    (FedEx, UPS, and other courier services use: Bethesda MD 20817)
    301-451-2020

  • Research at NEI
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Laboratories, Sections and Units
    • eyeGENE
    • Division of Epidemiology and Clinical Applications

    Office of the Scientific Director

    Sheldon S. Miller, Ph.D., Scientific Director
    David M. Schneeweis, Ph.D., Deputy Scientific Director

    Office of the Clinical Director

    Brian P. Brooks, M.D, Ph.D., Clinical Director
    Emily Y. Chew, M.D., Deputy Clinical Director

  • Education Programs
    • National Eye Health Education Program (NEHEP)
    • Diabetic Eye Disease Education Program
    • Glaucoma Education Program
    • Low Vision Education Program
    • Hispanic/Latino Program
    • Vision and Aging Program
    • African American Program
  • Training and Jobs
    • Jobs
    • NEI Summer Intern Program
    • Diversity In Vision Research & Ophthalmology (DIVRO)
    • Student Training Programs

    To search for current job openings visit HHS USAJobs

Home » News » Statements » Gene Transfer for Leber Congenital Amaurosis
Listen

Topics

Age-Related Macular Degeneration (AMD)
AIDS-related eye disease (cytomegalovirus [CMV] retinitis)
Amblyopia
Anophthalmia and Microphthalmia
Appointments
Astigmatism
Audacious Goals Challenge
Awards
Behçet’s Disease of the Eye
Bietti's Crystalline Dystrophy
Blepharitis
Blepharospasm
Cataracts
Clinical Studies
coloboma
Color Blindness
Convergence Insufficiency (CI)
Cornea
Diabetic Eye Disease
Dry Eye
Education Programs
Eye Cancer
Eye Surgery
Floaters
Gene
Glaucoma
Healthy Vision Month
Hispanic/Latino Americans
Histoplasmosis
Hyperopia
Idiopathic Intracranial Hypertension
Infancy
Infectious Eye Disease
Leber Congenital Amaurosis (LCA)
Low Vision
Macular Degeneration
Macular Edema
Macular Hole
Macular Pucker
Myopia
NEI
NEI Remembers
NEI Website
Optic Nerve Disorders
Pink Eye (Conjunctivitis)
Preschool
Rare Diseases
Refractive Errors
Refractive Surgery
Retina
Retinal Disease
Retinitis Pigmentosa
Retinoblastoma
Retinopathy of Prematurity (ROP)
Retinoschisis
Spanish
Spanish
Stargardt Disease
Stem Cells
Usher Syndrome
Uveitis/Inflammatory Eye Disease
Vision Screening
World Sight Day

Gene Transfer for Leber Congenital Amaurosis

Archived Page

The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.

04/27/08

Two groups of investigators have reported independently on their initial observations from Phase I clinical trials of gene transfer for Leber congenital amaurosis (LCA) caused by mutations in the RPE65 gene. The two papers appear in the April 27, 2008, online version of the New England Journal of Medicine. A third Phase I clinical trial, one supported directly by the National Eye Institute (NEI) of the National Institutes of Health (NIH), is ongoing, but initial observations have yet to be published. These Phase I clinical trials are designed as a preliminary assessment of the safety of gene transfer techniques in treating people with LCA.

People with LCA are born with severe visual impairment or develop vision loss early in childhood. "Proof-of-concept" studies in animal models of LCA demonstrated gene transfer techniques to be safe, effective, and long-lasting in restoring visual function. NEI has supported much of the basic, translational, and pre-clinical research leading up to these Phase I trials. For extensive background information on gene transfer and LCA, go to: http://www.nei.nih.gov/lca/.

The initial observations indicate that within a short follow-up period, five months to one year, gene transfer for LCA appears to be well-tolerated and safe. Phase I clinical trials are specifically designed to evaluate safety; they do not feature the standard statistical and methodological safeguards required to properly evaluate treatment effectiveness. Nonetheless, several of the reported observations suggest that gene transfer may be exerting modest effects in some of the treated individuals. Additional follow-up testing of the treated individuals should determine whether these effects are sustained. Durability of effects is crucial given the history of human gene therapy trials which have demonstrated that early gene expression can be thwarted by immunologic or other responses.

No conclusions can be made at present as to whether gene transfer will restore visual function in people with LCA or impede further progression of the disease. Additional important insights will be gained when investigators have the opportunity to examine the totality of the published data, including observations from the third Phase I clinical trial. These insights will enable investigators to refine the gene transfer techniques and will provide the preliminary information needed to design the Phase II and Phase III clinical trials that are necessary to determine both safety and effectiveness in a rigorous way.

  • NEI Home
  • Contact Us
  • A-Z Site Map
  • NEI on Social Media
  • Information in Spanish (Información en español)
  • Website, Social Media Policies and Other Important Links
  • NEI Employee Emergency Information
  • NEI Intranet (Employees Only)
  • Department of Health and Human Services
  • The National Institutes of Health
  • USA.gov

*PDF files require the free Adobe® Reader® software for viewing.

Technical questions about this website can be addressed to the NEI Website Manager.